Cutia Therapeutics is an investment holding company principally engaged in the dermatology biopharmaceutical business. The Company is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The Company is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The Company's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares)
319,466,511 (as at 30 Jun 2025)
Industry
Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date
12 Jun 2023
Financial Year Ends
31 Dec 2024
Chairman
Chen Lian Yong
Principal Office
Room 1919, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong
Place of Incorporation
Cayman Islands
Listing Category
Primary Listing
Primary Market
Depositary
DR Ratio
Description
Amount Outstanding
-
-
Subscription Rights per Unit
Subscription price/Strike price
Listing Date
The entitlement ratio in general represents the number of warrants required to be exercised into one share or one unit of the underlying asset (subject to any adjustments as may be necessary to reflect any capitalization, rights issue, distribution or the like).Entitlement Ratio
Subscription Period
Underlying Stock Code
Trading Currency